Development of Type 2 Diabetes Mellitus (T2DM) involves a lengthy and complex process from disease onset into symptom/complication manifesting in susceptible human beings. As a result, the cascade characters must be noticed at the earliest in patients.

In the early stage, many preventive measures (regular exercises, non-smoking and so on) or diet control can slow down the pace of the ongoing stages. Some far-reaching medical education systems for diabetes should be introduced to human beings in order to get medical intervention as early as possible [1]. Due to the asymptomic characteristics in early stages of metabolic syndromes, early technical diagnostics is inevitable yet imperfect now. People should be aware that high calorie food consumption is not the only factor to induce T2DM, some other unfavorable risk factors, such as habitually heavy drinking, somatic mutations, toxic compounds or sleep problems etc. [4-6]. can also trigger the incidence of T2DM. Thus, medical check-up for blood glucose concentration and levels should be carried out for people more than 40 years old every year.

Regular patho-therapeutic ideas and current drug targets are enlisted as following pathways;

1. What is the therapeutic outcome and differences between patients with T2DM of various origins?
2. What are genetic-molecular relationships between blood glucose increase and disease complications?
3. May a known variety of T2DM origins relevant to different individuals?
4. Can we successfully predict what kinds of diabetic-induced complications will emerge under specific conditions of patients?

T2DM is generated from genetic factors interaction with environmental influence. Personalized anti-Diabetic Therapy (PDT) may be a modern possibility that enables us to offer better therapeutics by integration of different technology and drugs. Pharmacogenetics (PG) [19], the widest utility of PDT has a great potentiality for drug selecting and dosing. To accomplish PG for T2DM treatments, human genetic/pathologic information must be known before therapeutics. With the advent and maturation of genomic sequencing technology [20], this kind of human genomic study might become practical to all patients and get information exponentially [20, 21]. But, who has the right to use human genomic information without regulation [22]. It is an ethical question that needs long-term debates between patients and healthcare providers. Currently, the “loss-of-function” by genetic mutation, such as leptin, insulin and their receptors or down-stream molecules is widely observed [21].

At this stage of technical capability, PG study for diabetes widely encompasses drug dosing (pharmacodynamics or pharmacokinetics issue) by genotypes of human metabolic enzymes. Due to the unpredictable nature of overall disease-related molecular alterations and metabolic abnormality, PG for various diabetic profiling is the important information different from metabolic enzymes (Fig. 2). Fig. (2) represents the outlook of PDT applications and promotion in the clinic. This type of PDT may be utilized in anti-diabetic treatments in the future [19-21].

Fig. (2). Proposed diagram of personalized anti-diabetic therapy.

Molecular and physiologic pathways and influences for T2DM are exemplified as the following parts;

Neural activity and circuits that control the appetite of patients is now located onto brain hypothalamic-pituitary area [17]. These kinds of brain activities are very important for human obesity and T2DM.

Abnormal metabolic conditions in human adipose tissues; their dysfunctional characteristics are based on adipose tissues, livers and other human organs [18].

Hormonal synthesis, secretion and resistance, such as insulin, leptin and others play key roles for patients’ obesity and diabetes [4-18]. Their synthesis, secretions and functional resistance are useful for individualized treatments of T2DM.

Energy homeostasis; a lot of patients with obesity and T2DM requires food control and heightened exercise activities [15, 16]. Human energy balance will decide human body weight gain or loss and further affect blood glucose levels. This energy issue is crucial for T2DM progress and managements [21].

Apart from these disease-induced pathways, other genetic and molecular issues may also involve [1-4]. With the growth of T2DM therapeutic study, higher efficiency of disease controls may be expected.

A great variety of herbs (>500 species) have been reported to be associated with T2DM [10]. A lot of articles reported their functionality and therapeutic activity in experimental settings. Nonetheless, only a few of these herbal drugs have been commercialized and widely utilized for T2DM prevention and treatments. Likewise, herbal therapy is one of the major avenues of diabetes mellitus therapeutic study and clinical development in the future [1, 23].

Most therapeutic data from anti-diabetic herbs are commonly based on multitude biochemical pathways, such as antioxidant activity, insulin synthesis, secretion and sensitivity, glucose uptake assistance, reduced glucose production from hepatocytes, anti-inflammatory activity and so on [22]. However, except a small number of countries, such as China, India and Germany, herbal drugs are not allowed for therapeutic purpose worldwide because of the requisite of high-quality and complexity of drug prescription in the clinic. From pharmacological perspective, the therapeutic study for herbal medicines should aim at specific drug targets and whole body regulation in clinical trials. Many animal diabetic models might not be the best vehicle for direct translations in the clinic.

To better utility of herbal drugs or recipes, some principle of TCM for diabetes might be properly established in the future [1]. Combinations of anti-diabetic therapy of modern medicine (chemical or biological therapy) and traditional (TCM) might be useful in the clinic.

Insulin-based therapy needs to improve for clinical feasibility. It commonly needs syringes and human-body injections, which lead to treatment inconvenience. Overall, some small-molecular chemicals having the insulin-configurations or insulin receptors binding activity might be potential oral anti-diabetic drugs for improving insulin-based therapy in the clinic [13, 14].

More recently, some capsules containing biological form of insulin were invented for patients needing insulin therapy [1]. This pharmaceutical innovation can provide greater feasibility for diabetic treatments in the future.

Approximately ten drugs have been widely used for T2DM worldwide. Table 2 outlines parts of these therapeutic drugs and potential applications in the clinic. Despite wide-ranges of drug developments, clinical T2DM treatments are commonly not curable [1, 23]. To most of these therapeutic options, drug treatments will be life-long for high-proportion of T2DM patients. After all, we need to know more about patho-therapeutic relations for curable therapy for patients with T2DM in the future.

Apart from herbal drugs, some insect products (Propolis) [25, 26] and fermented soybean (Natto) [4, 5] were also applicable in China and Japan for T2DM-related symptom control.

In the past, life-style adjustment is an effective way for the reductions of blood glucose and complication events for patient’s notification [27-29]. As usual, combination of life-style adjustment and meltformin is widely recommended by both American Diabetes Association (ADA) and European Association for Study of Diabetes (EAST). Table 2 shows a great number of therapeutic options chosen for anti-diabetic treatments. Certainly, we commonly use more than one therapeutic option in clinical trials. Generally, drug combination is more welcome for refractory chronic disease, like cancer and HIV/AIDS treatments comparing with mono-therapy [30-34]. It is a new concept of whether a systematic approach could be helpful from therapeutic combination.

Expanding pathological knowledge will be introduced to broader ranges of people for noticing and treating patients on disease onset. Genome Wide Association Study (GWAS) between patients and normal people may be breakthroughs for T2DM pathogenesis and treatments - the exponentially explosion of human genomic data.

Genetic or molecular study of disease progression, drug pharmacology, mechanisms of action for drug activity/toxicity. Establish personalized anti-diabetic therapy in the clinic. Develop higher therapeutic-index drugs, such as natural chemotherapeutic anti-diabetic drugs [35, 36]. Pharmaceutically improves insulin-based treatments from needle to oral. Budget control in drug developments and cost-effective in clinical treatment selections will be more optimized [37].

Global cooperation is inevitable, especially invitation of mathematical majored students and scholar in this medical campaign [38-40]. Mathematical solution of disease risks and occurrence is given in Equation 1 [41].

(1)

where, T: incidence and risks of T2DM in random human population